secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001140361-24-046314
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Grace Therapeutics reports Q2 net loss $3.4M; Phase 3 STRIVE-ON data due Q1 2025; cash into Q2 2026
--------------------------------------------------------------------------------

- Net loss of $3.4M ($0.30 per share) vs $3.3M ($0.43 per share) in prior year; R&D spend up to $3.0M on pivotal trial.
- Phase 3 STRIVE-ON safety trial enrollment complete; data readout expected Q1 2025; NDA submission for GTx-104 on track for 1H 2025.
- Cash and equivalents $15.1M; projected runway into Q2 2026.
- Redomiciled to Delaware and rebranded to Grace Therapeutics; ticker changed to GRCE on Nasdaq.
- Hosting KOL event on aSAH on Nov 20, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000114036124046314/0001140361-24-046314-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000114036124046314/ef20038398_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-046314

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer